Hepatitis C protease and polymerase inhibitors in development

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C Virus (HCV) infection is a significant global health concern.
• Current therapies offer limited efficacy, with sustained virologic response (SVR) rates around 50%, particularly for HCV genotype 1.
• SVR rates are even lower in HIV-HCV co-infected patients (30-40%).

Purpose of the Study:

• To review novel anti-HCV therapies currently in development.
• To discuss agents targeting essential HCV enzymes like NS3 protease and NS5B polymerase.
• To present early clinical trial data on efficacy, safety, and resistance profiles of new anti-HCV drugs.

Main Methods:

• Focus on inhibitors of Hepatitis C Virus (HCV) NS3 protease and NS5B polymerase.
• Identification of agents that have advanced to late-stage clinical trials.
• Review of early trial results for efficacy, safety, and drug resistance.

Main Results:

• Two protease inhibitors (telaprevir, boceprevir) and three polymerase inhibitors (valopicitabine, R1626, HCV-796) are in late-stage clinical trials.
• Telaprevir is the most clinically advanced among these novel agents.
• Early data on efficacy, safety, and resistance profiles are emerging for these compounds.

Conclusions:

• Novel direct-acting antiviral agents targeting HCV enzymes represent a promising new therapeutic strategy.
• These agents offer potential for improved SVR rates in patients with HCV, including those with prior treatment failures.
• Further clinical evaluation is crucial to establish the role of these drugs in HCV management.